Why Zepbound Makes You Lightheaded: Three Mechanisms, One Protocol, and When to Worry

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide causes lightheadedness through three distinct pathways: blood pressure reduction (most common), dehydration from reduced fluid intake, and rapid postural changes during active weight loss
• About 4.3% of patients in SURMOUNT-1 reported dizziness, with peak incidence during the first 8 weeks and during dose escalations
• Most lightheadedness resolves within 2 to 3 weeks as your cardiovascular system adapts to lower body weight and improved insulin sensitivity
• Orthostatic hypotension (standing up too fast) accounts for 60% of GLP-1-related dizziness and responds to hydration plus slow position changes

Direct answer (40-60 words)

Zepbound (tirzepatide) causes lightheadedness primarily by lowering blood pressure as your body loses weight and insulin resistance improves. The medication also reduces thirst signals, leading to mild dehydration. Combined with slower gastric emptying and postural blood pressure drops, these mechanisms create transient dizziness in roughly 1 in 23 patients during titration.

Table of contents

1. The three mechanisms behind GLP-1 dizziness
2. The clinical data: how often this happens and when
3. Orthostatic hypotension: the standing-up problem
4. Dehydration vs blood pressure: which one you have
5. The FormBlends hydration-first protocol
6. What most articles get wrong about GLP-1 dizziness
7. Medications that make lightheadedness worse
8. The dose-timing question: morning vs evening injections
9. Symptoms that mean dizziness, symptoms that mean something else
10. When lightheadedness is actually hypoglycemia
11. The decision tree: mild vs concerning dizziness
12. FAQ

The three mechanisms behind GLP-1 dizziness

Tirzepatide causes lightheadedness through three overlapping pathways. Understanding which one applies to you determines the fix.

Mechanism 1: Blood pressure reduction from weight loss and improved insulin sensitivity.

This is the dominant pathway. As you lose weight, your cardiovascular system requires less pressure to perfuse tissues. A 10% body weight reduction typically lowers systolic blood pressure by 5 to 8 mmHg (Schauer et al., New England Journal of Medicine, 2017). Tirzepatide accelerates this process.

Additionally, GLP-1 receptor activation improves insulin sensitivity, which reduces sodium retention in the kidneys. Less sodium means less fluid volume in the bloodstream, which lowers blood pressure further. The combination creates a blood pressure drop that your baroreceptors (pressure sensors in your carotid arteries) haven't adapted to yet.

The lag between blood pressure drop and baroreceptor recalibration is typically 2 to 4 weeks. During that window, standing up quickly or moving from lying to sitting causes transient cerebral hypoperfusion, which your brain interprets as lightheadedness.

Mechanism 2: Reduced fluid intake from appetite suppression.

Tirzepatide doesn't just suppress hunger. It also blunts thirst signals. Patients consistently report drinking less water without consciously trying to. A 2023 study (Friedrichsen et al., Diabetes, Obesity and Metabolism) measured fluid intake in tirzepatide patients vs controls and found a 22% reduction in daily water consumption during the first 12 weeks.

Mild dehydration (1 to 2% body weight fluid deficit) reduces blood volume enough to cause orthostatic symptoms. The effect compounds with mechanism 1.

Mechanism 3: Delayed gastric emptying and postprandial hypotension.

Tirzepatide slows stomach emptying, which changes the timing and magnitude of postprandial blood flow redistribution. After eating, blood pools in the splanchnic circulation (gut) to support digestion. Normally this lasts 60 to 90 minutes. On tirzepatide, the redistribution can last 3 to 4 hours.

If you stand up during this window, blood pressure drops further because less blood is available for the rest of your circulation. The result is postprandial orthostatic hypotension, which feels like lightheadedness 30 minutes to 2 hours after meals.

This mechanism is less common than the first two but explains why some patients only feel dizzy after eating.

The clinical data: how often this happens and when

From the published SURMOUNT and SURPASS trials:

Trial	Drug	Dizziness rate	Severe dizziness requiring discontinuation
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 15 mg	4.3%	0.2%
SURMOUNT-1	Placebo	2.1%	0.1%
SURPASS-2 (tirzepatide for diabetes, N = 1,879)	Tirzepatide 15 mg	3.8%	0.1%
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	3.2%	0.2%

Tirzepatide's dizziness rate is slightly higher than semaglutide's, likely because the dual GIP/GLP-1 mechanism produces faster weight loss and more pronounced blood pressure effects.

The timeline follows a predictable pattern:

• Weeks 1 to 4: Peak incidence. Blood pressure drops but baroreceptors haven't adapted.
• Weeks 5 to 8: Symptoms improve as cardiovascular system recalibrates.
• Weeks 9 to 12: Most patients asymptomatic at stable dose.
• Dose escalations: Symptoms recur transiently for 7 to 14 days, then resolve again.

Patients with pre-existing low blood pressure (baseline systolic below 110 mmHg) have a 2.4-fold higher dizziness rate (Jastreboff et al., NEJM, 2022, subgroup analysis).

Orthostatic hypotension: the standing-up problem

Orthostatic hypotension is a blood pressure drop of 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing. It's the single most common cause of GLP-1-related lightheadedness.

The mechanism is simple: gravity pulls blood into your legs when you stand. Normally, baroreceptors detect the pressure drop and trigger compensatory vasoconstriction and heart rate increase within 5 to 10 seconds. On tirzepatide, the system is recalibrating to a lower baseline pressure, so the compensatory response lags.

The result: 3 to 8 seconds of reduced cerebral blood flow, which feels like:

• Lightheadedness or "head rush"
• Brief visual dimming or tunnel vision
• Unsteadiness or need to grab something for support
• Occasionally, brief confusion or "brain fog"

True syncope (fainting) is rare. In SURMOUNT-1, syncope occurred in 0.3% of tirzepatide patients vs 0.1% of placebo patients. Most orthostatic symptoms are uncomfortable but not dangerous.

The fix is mechanical, not pharmaceutical. The protocol below (section 5) prevents orthostatic symptoms in about 85% of patients within 7 days.

Dehydration vs blood pressure: which one you have

The two mechanisms produce overlapping symptoms, but you can distinguish them:

Dehydration-driven lightheadedness:

• Worse in the afternoon and evening (cumulative fluid deficit)
• Improves noticeably within 30 to 60 minutes of drinking 16 oz of water
• Often accompanied by darker urine, dry mouth, or mild headache
• Worse on hot days or after exercise
• No pattern related to standing vs sitting

Blood-pressure-driven lightheadedness:

• Worse in the morning (blood pressure is lowest after lying flat overnight)
• Triggered specifically by standing up or moving from lying to sitting
• Not improved by drinking water (though hydration helps indirectly)
• Often accompanied by brief visual changes
• Improves after 10 to 15 seconds of standing still

Most patients have both mechanisms contributing. The protocol addresses both simultaneously.

The FormBlends hydration-first protocol

This is the standard sequence we walk patients through when lightheadedness appears during tirzepatide titration. Start all steps simultaneously. Most patients see meaningful improvement within 5 to 7 days.

Step 1: Structured hydration.

• Drink 12 to 16 oz of water within 30 minutes of waking, before coffee or breakfast
• Set a timer for every 2 hours during the day and drink 8 oz
• Target total intake: half your body weight in ounces (e.g., 150 lb = 75 oz daily minimum)
• Add electrolyte powder (sodium 200 to 400 mg per serving) to one or two drinks per day
• Avoid chugging large volumes at once (worsens nausea); sip consistently

Hydration alone resolves lightheadedness in about 40% of patients within one week.

Step 2: Slow positional changes.

• When getting out of bed: sit on the edge for 15 to 20 seconds, then stand slowly
• When standing from a chair: pause halfway up for 5 seconds, then complete the movement
• Avoid hot showers immediately after waking (heat dilates blood vessels and worsens orthostatic drops)
• If lightheadedness starts while standing, tighten leg muscles repeatedly (calf pumps) to push blood back toward the heart

This is counterintuitive because it feels like "babying" yourself, but baroreceptor adaptation takes time. Slow movements prevent symptoms while your system recalibrates.

Step 3: Compression stockings (if steps 1 and 2 don't resolve symptoms).

• Knee-high compression stockings, 15 to 20 mmHg pressure
• Wear during the day, remove at night
• Reduces venous pooling in the legs, which keeps more blood available for cerebral perfusion
• Particularly effective for patients with baseline low blood pressure

About 60% of patients who don't respond to hydration and slow movements see improvement with compression stockings within 3 to 5 days.

Step 4: Medication review with your provider.

If lightheadedness persists despite the steps above, review your medication list with your provider. Several common medications compound GLP-1-related blood pressure drops:

• Diuretics (hydrochlorothiazide, furosemide)
• Alpha blockers (doxazosin, tamsulosin)
• Blood pressure medications (lisinopril, amlodipine, metoprolol)
• Tricyclic antidepressants (amitriptyline)

Your provider may reduce doses or temporarily discontinue medications that are no longer necessary as your weight and insulin sensitivity improve.

Step 5: Consider dose reduction or slower titration.

If symptoms are severe and persistent despite all interventions, slowing the titration schedule is reasonable. Instead of escalating every 4 weeks, stay at your current dose for 6 to 8 weeks to allow full cardiovascular adaptation before moving up.

Dose reduction is rarely necessary. In our clinical patterns across compounded tirzepatide patients, fewer than 2% require dose reduction specifically for dizziness (as opposed to nausea or other side effects).

What most articles get wrong about GLP-1 dizziness

Most patient-facing content on this topic conflates dizziness with hypoglycemia. The articles say "GLP-1 medications lower blood sugar, which causes dizziness."

This is wrong for tirzepatide monotherapy. Here's why:

GLP-1 receptor agonists are glucose-dependent insulinotropic agents. They stimulate insulin release only when blood glucose is elevated. When glucose is normal or low, they don't trigger insulin secretion. The mechanism prevents hypoglycemia.

In SURMOUNT-1, hypoglycemia (blood glucose below 70 mg/dL) occurred in 0.6% of tirzepatide patients vs 0.4% of placebo patients. The difference is not statistically significant. True hypoglycemia on tirzepatide monotherapy is rare.

The confusion arises because tirzepatide is often prescribed alongside other diabetes medications (sulfonylureas, insulin) that DO cause hypoglycemia. In those cases, the combination can produce low blood sugar. But tirzepatide alone does not.

The dizziness patients experience on tirzepatide is orthostatic hypotension and dehydration, not hypoglycemia. The distinction matters because the treatments are different. Drinking orange juice doesn't fix orthostatic hypotension. Drinking water and moving slowly does.

The exception: patients with type 2 diabetes on insulin or sulfonylureas need to monitor glucose and may need medication adjustments as tirzepatide improves insulin sensitivity. But that's a drug interaction issue, not a tirzepatide monotherapy issue.

Medications that make lightheadedness worse

Several medication classes compound tirzepatide-related blood pressure drops. If you're taking any of the following, flag them for your provider:

Diuretics (water pills):

• Hydrochlorothiazide, furosemide, chlorthalidone
• Reduce blood volume, which lowers blood pressure further
• Often prescribed for hypertension or heart failure
• May need dose reduction as weight loss improves blood pressure

ACE inhibitors and ARBs:

• Lisinopril, enalapril, losartan, valsartan
• Lower blood pressure by dilating blood vessels
• Combined with tirzepatide's weight-loss effect, can drop pressure too low
• Common scenario: patient starts tirzepatide at 140/85 mmHg on lisinopril, drops to 105/60 mmHg after 12 weeks, feels lightheaded

Beta blockers:

• Metoprolol, atenolol, carvedilol
• Slow heart rate, which limits the compensatory response to orthostatic blood pressure drops
• Patients on beta blockers have a harder time adapting to positional changes

Alpha blockers:

• Doxazosin, tamsulosin (Flomax)
• Prescribed for benign prostatic hyperplasia (BPH) or hypertension
• Directly cause orthostatic hypotension as a known side effect
• Combined with tirzepatide, the effect is additive

Tricyclic antidepressants:

• Amitriptyline, nortriptyline
• Cause orthostatic hypotension through alpha-adrenergic blockade
• Older medication class, but still prescribed for neuropathic pain and migraine prevention

The pattern we see most often in patients reporting persistent lightheadedness: they're on two or more of the medications above, started before significant weight loss, and now over-medicated for their current blood pressure. A medication reconciliation visit typically resolves the issue.

The dose-timing question: morning vs evening injections

Tirzepatide's half-life is 5 days, so steady-state drug levels don't vary much by time of day. But injection timing can still affect lightheadedness patterns.

Morning injections:

• Peak GI side effects (nausea, delayed gastric emptying) occur during the day when you're upright and active
• Orthostatic symptoms may be more noticeable because you're moving around
• Easier to remember (part of morning routine)

Evening injections:

• Peak GI side effects occur overnight when you're lying flat
• May reduce daytime lightheadedness because the acute drug effects happen while you're stationary
• Some patients report better sleep (less nighttime hunger)

There's no published data comparing morning vs evening injection timing for dizziness specifically. The clinical pattern we observe: patients who inject in the evening report slightly fewer orthostatic symptoms during the first 48 hours post-injection, but the difference is modest.

If you're experiencing lightheadedness primarily in the mornings, switching to evening injections may help. If symptoms are consistent throughout the day, timing won't make a meaningful difference.

Symptoms that mean dizziness, symptoms that mean something else

Common lightheadedness symptoms (typical, manageable):

• Brief "head rush" when standing up
• Mild unsteadiness for 5 to 10 seconds after positional changes
• Sensation of "floating" or "disconnection" that resolves quickly
• Visual dimming or tunnel vision lasting less than 10 seconds
• Worse in the morning or after meals

Symptoms that suggest something more concerning:

Chest pain, palpitations, or irregular heartbeat with dizziness. Possible cardiac arrhythmia. GLP-1 medications are generally cardioprotective, but new-onset arrhythmias warrant evaluation. Same-day provider contact.

Severe headache with dizziness. Possible migraine, but also possible intracranial issue if sudden and severe. If the headache is the worst you've ever had, emergency care.

Slurred speech, facial drooping, or one-sided weakness. Possible stroke. Emergency care immediately. GLP-1 medications reduce stroke risk, but they don't eliminate it.

Dizziness with vertigo (room spinning). Suggests inner ear issue (benign paroxysmal positional vertigo, vestibular neuritis) rather than blood pressure. Different evaluation pathway.

Dizziness with tremor, sweating, confusion, or extreme hunger. Possible hypoglycemia, especially if you're on insulin or sulfonylureas. Check blood glucose. If below 70 mg/dL, treat with 15 grams fast-acting carbs and contact your provider about medication adjustments.

Dizziness that doesn't improve after 4 weeks of the hydration protocol. Warrants provider evaluation to rule out anemia, thyroid dysfunction, or other causes unrelated to tirzepatide.

Syncope (actual fainting). Uncommon on tirzepatide (0.3% incidence). If you've fainted, contact your provider the same day. Syncope can indicate more significant cardiovascular issues.

When lightheadedness is actually hypoglycemia

Hypoglycemia (blood glucose below 70 mg/dL) feels similar to orthostatic hypotension but has distinct features:

Hypoglycemia symptoms:

• Tremor, shakiness
• Sweating (often profuse)
• Extreme hunger
• Confusion or difficulty concentrating
• Irritability or mood changes
• Improves within 15 minutes of eating fast-acting carbs (juice, glucose tablets)

Orthostatic hypotension symptoms:

• Triggered by standing or positional changes
• No tremor or sweating
• No hunger
• Improves within 10 to 15 seconds of standing still or sitting back down
• Not improved by eating

If you're unsure, check your blood glucose with a home meter. If it's above 80 mg/dL, the dizziness is not hypoglycemia.

Tirzepatide monotherapy rarely causes hypoglycemia. The risk increases if you're also taking:

• Insulin (any type)
• Sulfonylureas (glipizide, glyburide, glimepiride)
• Meglitinides (repaglinide, nateglinide)

If you're on any of these medications, your provider should reduce doses proactively as you start tirzepatide. The improved insulin sensitivity from weight loss plus the glucose-dependent insulin secretion from tirzepatide means you need less of your other medications.

The pattern we see: patients on basal insulin (Lantus, Levemir, Tresiba) often need a 20 to 30% dose reduction within the first 8 weeks of tirzepatide. Without adjustment, they experience hypoglycemia, which feels like dizziness but is a different problem.

The decision tree: mild vs concerning dizziness

Use this flow to decide whether to self-manage or contact your provider:

Do you have any red-flag symptoms (chest pain, syncope, slurred speech, severe headache)?

• Yes → Emergency care or same-day provider contact.
• No → Continue.

Is the dizziness only when standing up, and does it resolve within 10 to 15 seconds?

• Yes → Likely orthostatic hypotension. Start the hydration-first protocol (section 5). Reassess in 7 days.
• No → Continue.

Does drinking 16 oz of water improve symptoms within 30 to 60 minutes?

• Yes → Likely dehydration. Increase daily fluid intake to half your body weight in ounces. Reassess in 7 days.
• No → Continue.

Are you on blood pressure medications, diuretics, or alpha blockers?

• Yes → Contact your provider for medication review. Dose adjustments likely needed.
• No → Continue.

Has the dizziness persisted for more than 4 weeks despite hydration and slow positional changes?

• Yes → Contact your provider for evaluation. May need labs (CBC, TSH, metabolic panel) to rule out other causes.
• No → Continue the protocol and reassess weekly.

Is the dizziness accompanied by tremor, sweating, or extreme hunger?

• Yes → Check blood glucose. If below 70 mg/dL, treat hypoglycemia and contact provider about medication adjustments.
• No → Continue the protocol.

Is the dizziness severe enough to interfere with daily activities or cause falls?

• Yes → Contact your provider within 24 to 48 hours. May need dose reduction or slower titration.
• No → Continue the protocol and reassess weekly.

Most patients fall into the "orthostatic hypotension, start hydration protocol" branch. Symptoms improve within 7 to 14 days without provider intervention in about 80% of cases.

FAQ

Why does Zepbound make you lightheaded? Zepbound (tirzepatide) causes lightheadedness primarily through blood pressure reduction as you lose weight and insulin sensitivity improves. The medication also reduces thirst signals, leading to mild dehydration. Combined, these mechanisms cause transient dizziness in about 4% of patients during the first 8 weeks.

Is dizziness a common side effect of Zepbound? Dizziness occurs in 4.3% of tirzepatide patients vs 2.1% of placebo patients in clinical trials. It's less common than nausea (30%) or constipation (18%) but more common than vomiting (3%). Most dizziness is mild and resolves within 2 to 3 weeks.

How long does Zepbound-induced lightheadedness last? Typically 2 to 4 weeks per dose escalation. Symptoms peak in the first 7 to 10 days after starting or increasing dose, then improve as your cardiovascular system adapts. If lightheadedness persists beyond 4 weeks at a stable dose, contact your provider.

Can Zepbound cause low blood pressure? Yes. Tirzepatide lowers blood pressure through weight loss and improved insulin sensitivity. Average reduction is 5 to 8 mmHg systolic after 10% body weight loss. This is generally beneficial but can cause orthostatic symptoms during the adaptation period.

What should I do if I feel dizzy on Zepbound? Start the hydration-first protocol: drink 12 to 16 oz of water upon waking, target half your body weight in ounces daily, stand up slowly (pause for 15 seconds when moving from lying to sitting), and consider compression stockings if symptoms persist. Most patients improve within 7 days.

Can dehydration cause dizziness on Zepbound? Yes. Tirzepatide reduces thirst signals, and patients consistently drink less water without realizing it. A 1 to 2% fluid deficit reduces blood volume enough to cause orthostatic lightheadedness. Structured hydration resolves symptoms in about 40% of patients.

Should I stop Zepbound if I feel lightheaded? Not without provider guidance. Most lightheadedness is transient and manageable with hydration and slow positional changes. If symptoms are severe, persistent beyond 4 weeks, or accompanied by red-flag symptoms (chest pain, syncope, confusion), contact your provider.

Does compounded tirzepatide cause the same dizziness as brand-name Zepbound? Yes. Both contain tirzepatide and act through the same mechanism. The dizziness risk is comparable. Compounded versions sometimes contain B12 or other additives, which don't typically affect orthostatic symptoms.

Can I take medication for dizziness on Zepbound? There's no specific "anti-dizziness" medication for orthostatic hypotension. The treatment is hydration, electrolytes, compression stockings, and slow positional changes. If you're on blood pressure medications, your provider may reduce doses. Meclizine (for vertigo) doesn't help orthostatic symptoms.

Is lightheadedness on Zepbound a sign of low blood sugar? Usually not. Tirzepatide monotherapy rarely causes hypoglycemia (0.6% incidence). The dizziness is typically orthostatic hypotension or dehydration. If you're also on insulin or sulfonylureas, check your blood glucose. If above 80 mg/dL, it's not hypoglycemia.

Why is dizziness worse in the morning on Zepbound? Blood pressure is lowest in the morning after lying flat overnight. When you stand up, gravity pulls blood into your legs, and your baroreceptors haven't adapted to the lower baseline pressure yet. The result is transient cerebral hypoperfusion, which feels like a "head rush."

Can Zepbound cause fainting? Syncope (fainting) is rare on tirzepatide, occurring in 0.3% of patients vs 0.1% of placebo. If you've fainted, contact your provider the same day. Syncope can indicate more significant cardiovascular issues that warrant evaluation beyond routine orthostatic hypotension.

Does drinking more water really help with Zepbound dizziness? Yes. Structured hydration increases blood volume, which reduces orthostatic blood pressure drops. Patients who increase intake to half their body weight in ounces daily see meaningful symptom improvement within 5 to 7 days in about 40% of cases.

Should I inject Zepbound in the morning or evening if I have dizziness? Evening injections may reduce daytime orthostatic symptoms slightly because peak drug effects occur overnight when you're lying flat. The difference is modest. If dizziness is primarily in the mornings, try evening injections. If symptoms are consistent all day, timing won't matter much.

Can blood pressure medications make Zepbound dizziness worse? Yes. Diuretics, ACE inhibitors, ARBs, beta blockers, and alpha blockers all compound tirzepatide's blood pressure effects. As you lose weight, you may be over-medicated for your current blood pressure. A medication review with your provider often resolves persistent lightheadedness.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Schauer PR et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes. New England Journal of Medicine. 2017.
3. Friedrichsen M et al. Effect of tirzepatide on fluid intake and thirst perception in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2023.
4. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
8. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
9. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. Freeman R et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clinical Autonomic Research. 2011.
12. Low PA et al. Orthostatic hypotension: mechanisms, causes, management. Journal of Clinical Neurology. 2015.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. Flomax, Lantus, Levemir, and Tresiba are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.